aTyr Pharma, Inc. (ATYR)

aTyr Pharma, Inc. (ATYR) Healthcare & Pipeline Overview

aTyr Pharma, Inc. is a biotherapeutics company specializing in the discovery and development of medicines targeting novel immunological pathways. Their lead candidate, efzofitimod, is undergoing Phase III trials for pulmonary sarcoidosis and Phase 1b/2a trials for other interstitial lung diseases, positioning them within the competitive biotechnology sector.

What Is the Investment Thesis for ATYR?

aTyr Pharma's investment thesis centers on the potential of efzofitimod to address unmet needs in pulmonary sarcoidosis and other ILDs. The Phase III clinical trial for pulmonary sarcoidosis represents a near-term catalyst, with positive data potentially driving significant value. The company's pipeline of preclinical programs, including ATYR0101 and ATYR0750, offers longer-term growth opportunities in fibrosis and liver disorders. However, the company's negative profit margin of -39009.5% and gross margin of -11754.7% highlight the significant financial risks associated with biotechnology companies, particularly those in the clinical development stage. Successful commercialization of efzofitimod and advancement of the preclinical pipeline are critical for long-term value creation.

Based on FMP financials and quantitative analysis

ATYR Key Highlights

• aTyr Pharma's lead therapeutic candidate, efzofitimod, is in Phase III clinical trial for pulmonary sarcoidosis.
• The company has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
• aTyr Pharma is developing ATYR0101, a fusion protein, for the treatment of fibrosis, currently in preclinical development.
• The company's market capitalization is approximately $0.08 billion as of May 7, 2026.
• aTyr Pharma's beta of 0.56 indicates lower volatility compared to the overall market.

Who Are ATYR's Competitors?

ATYR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATYR's Key Strengths?

• Novel tRNA synthetase biology platform.
• Lead therapeutic candidate, efzofitimod, in Phase III clinical trial.
• Collaboration agreement with Kyorin Pharmaceutical Co., Ltd.
• Focus on unmet needs in severe respiratory diseases and other immune-mediated conditions.

What Are ATYR's Weaknesses?

• Negative profit margin and gross margin.
• Reliance on the success of efzofitimod.
• Limited financial resources compared to larger pharmaceutical companies.
• Preclinical programs are early stage and high risk.

What Could Drive ATYR Stock Higher?

• Data readout from Phase III clinical trial of efzofitimod for pulmonary sarcoidosis.
• Initiation of Phase III clinical trials for efzofitimod in other interstitial lung diseases (ILDs).
• IND filing for ATYR0101 for the treatment of fibrosis.
• Continued enrollment and progress in Phase 1b/2a clinical trials for efzofitimod in other ILDs.

What Are the Key Risks for ATYR?

• Failure of efzofitimod in Phase III clinical trial.
• Competition from other pharmaceutical companies developing therapies for pulmonary sarcoidosis and other ILDs.
• Regulatory hurdles and delays in obtaining FDA approval.
• Difficulty in raising capital to fund research and development.
• High cash burn rate due to ongoing clinical trials and research activities.

What Are the Growth Opportunities for ATYR?

• Growth opportunity 1: Successful completion of the Phase III clinical trial for efzofitimod in pulmonary sarcoidosis represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, addressing a market with substantial unmet need. The global pulmonary sarcoidosis market is projected to reach hundreds of millions of dollars, offering aTyr Pharma a significant revenue stream if efzofitimod proves to be an effective treatment. Timeline: Anticipated data readout within the next 12-18 months.
• Growth opportunity 2: Expansion of efzofitimod's clinical development into other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, offers another avenue for growth. These ILDs represent distinct patient populations with limited treatment options, providing aTyr Pharma with the opportunity to address additional unmet needs and expand its market reach. The ILD market is estimated to be worth billions of dollars globally. Timeline: Ongoing Phase 1b/2a trials with potential for Phase III initiation in 2027.
• Growth opportunity 3: Advancement of the preclinical pipeline, including ATYR0101 for fibrosis and ATYR0750 for liver disorders, represents a longer-term growth opportunity. These programs target large and growing markets with significant unmet needs. Successful development and commercialization of these therapies could diversify aTyr Pharma's product portfolio and revenue streams. The fibrosis and liver disease markets are each estimated to be multi-billion dollar markets. Timeline: IND filing for ATYR0101 anticipated in 2028.
• Growth opportunity 4: Leveraging the collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan provides aTyr Pharma with access to the Japanese market, one of the largest pharmaceutical markets in the world. This partnership allows aTyr Pharma to benefit from Kyorin's local expertise and infrastructure, accelerating the commercialization of efzofitimod in Japan. The Japanese ILD market is a significant portion of the global market. Timeline: Commercialization in Japan contingent on regulatory approval, expected post-Phase III success.
• Growth opportunity 5: Exploring new therapeutic applications of tRNA synthetase biology beyond respiratory and liver diseases represents a longer-term growth opportunity. aTyr Pharma's expertise in this area could lead to the discovery and development of novel therapies for other immune-mediated conditions, expanding the company's pipeline and market reach. This could include autoimmune diseases or other inflammatory conditions. Timeline: Ongoing research and development with potential for new program initiation in 2029.

What Opportunities Does ATYR Have?

• Successful completion of Phase III clinical trial for efzofitimod.
• Expansion of efzofitimod's clinical development into other ILDs.
• Advancement of preclinical pipeline, including ATYR0101 and ATYR0750.
• Expansion into new therapeutic areas beyond respiratory and liver diseases.

What Threats Does ATYR Face?

• Failure of efzofitimod in Phase III clinical trial.
• Competition from other pharmaceutical companies developing therapies for pulmonary sarcoidosis and other ILDs.
• Regulatory hurdles and delays in obtaining FDA approval.
• Difficulty in raising capital to fund research and development.

What Are ATYR's Competitive Advantages?

• Proprietary tRNA synthetase biology platform for discovering novel therapeutic targets.
• Patent protection for efzofitimod and other drug candidates.
• Clinical data supporting the safety and efficacy of efzofitimod.
• Collaboration agreement with Kyorin Pharmaceutical Co., Ltd. provides access to the Japanese market.

What Does ATYR Do?

aTyr Pharma, Inc., founded in 2005 and headquartered in San Diego, California, is a biotherapeutics company focused on the discovery and development of innovative medicines based on novel immunological pathways. The company's primary focus is on addressing unmet needs in severe respiratory diseases and other immune-mediated conditions. Their lead therapeutic candidate, efzofitimod, a selective modulator of NRP2 (neuropilin-2), is currently in Phase III clinical development for pulmonary sarcoidosis, a chronic inflammatory disease affecting the lungs. Additionally, efzofitimod is in Phase 1b/2a clinical trials for the treatment of other interstitial lung diseases (ILDs), including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. aTyr Pharma is also advancing a pipeline of preclinical programs, including ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is being developed for the treatment of fibrosis. Another preclinical asset, ATYR0750, a domain of alanyl-tRNA synthetase, is being explored for the treatment of liver disorders. The company's approach leverages its expertise in tRNA synthetase biology to develop novel therapies that modulate immune cell function and address the underlying causes of disease. aTyr Pharma has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan, expanding its geographic reach and potential market opportunities. The company operates with a team of 56 employees, focusing on research, development, and clinical advancement of its therapeutic candidates.

What Products and Services Does ATYR Offer?

• Discovers and develops medicines based on novel immunological pathways.
• Focuses on severe respiratory diseases and other immune-mediated conditions.
• Develops efzofitimod, a selective modulator of NRP2, for pulmonary sarcoidosis and other interstitial lung diseases (ILDs).
• Advances preclinical programs, including ATYR0101 for fibrosis and ATYR0750 for liver disorders.
• Collaborates with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan.
• Leverages tRNA synthetase biology to develop novel therapies that modulate immune cell function.

How Does ATYR Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from agencies like the FDA for commercialization.
• Out-licenses or partners with other pharmaceutical companies for commercialization and distribution, as seen with Kyorin Pharmaceutical.

What Industry Does ATYR Operate In?

aTyr Pharma operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial financial risk. The market for pulmonary sarcoidosis and other interstitial lung diseases is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Competition includes established pharmaceutical companies and other biotechnology firms developing therapies for respiratory and immune-mediated diseases. aTyr Pharma's focus on tRNA synthetase biology and novel immunological pathways differentiates it from some competitors, but the company faces challenges in securing regulatory approval and commercializing its products.

Who Are ATYR's Key Customers?

• Patients suffering from pulmonary sarcoidosis and other interstitial lung diseases (ILDs).
• Patients with fibrosis.
• Patients with liver disorders.
• Pharmaceutical companies through licensing and collaboration agreements.

ATYR Financials

ATYR Latest News

ATYR Analyst Consensus

ATYR MoonshotScore

Common Questions About ATYR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources